Perceptive Advisors LLC Bio Atla, Inc. Transaction History

Perceptive Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $92,710 - $232,140	73,000 New	73,000 $179,000
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $2.9 Million - $12.4 Million	-661,200 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $3.59 Million - $5.84 Million	-188,826 Reduced 22.21%	661,200 $13 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $4.84 Million - $7.2 Million	164,507 Added 24.0%	850,026 $25 Million
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $26.1 Million - $38.5 Million	685,519 New	685,519 $29.1 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.